- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06225050
M-2018-334 in Hematological Malignancies (HAPLO2022)
January 29, 2024 updated by: Miltenyi Biomedicine GmbH
A Single-center Pilot Study Using TCRα/β and CD45RA Depleted Stem Cell Grafts From Haploidentical Donors for Hematopoietic Cell Transplantation in Adults(HAPLO2022)
This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Premchand Pastula
- Phone Number: +49 15144059503
- Email: clinicaltrials_gov_ClinDev@miltenyibiotec.de
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients, between 18 years to 75 years of age, with high-risk hematological malignancy requiring an allogeneic hematopoietic stem cell transplantation (AlloHCT), but do not have an HLA-matched donor available
Exclusion Criteria:
- <3 months after preceding autologous transplantation or prior AlloHCT
- History of neurological impairment (active seizures, severe peripheral neuropathy, signs of leukoencephalopathy, active CNS infection)
- Active fungal infections with radiological and clinical progression
- Liver function abnormalities with bilirubin >2 mg/dL and elevation of transaminases higher than 400 U/L
- Chronic active viral hepatitis
- Cardiac dysfunction: adult patients ejection fraction <50% on echocardiography
- Patients with uncontrolled, >grade II hypertension (per Common Toxicity Criteria, CTC)
- Creatinine clearance <60 mL/min/1.73m2
- Respiratory failure necessitating supplemental oxygen
- HIV infection
- Positive anti-donor HLA antibody
- Treatment with checkpoint inhibitors in the period between 3 months prior to and 3 months after transplantation
- Female patients who are pregnant or breast feeding, or adults of reproductive potential not willing to use an effective method of birth control during study treatment and for at least 12 months thereafter. Note: Women of childbearing potential must have a negative serum pregnancy test at study entry
- Concurrent severe or uncontrolled medical disease (e.g., uncontrolled diabetes, myocardial infarction within 6 months prior to the study) which by assessment of the treating physician could compromise participation in the study
- Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction).
- Patients unwilling or unable to comply with the protocol or unable to give informed consent
- Treatment with any investigational product within 4 weeks prior to study treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HSC Recipient
PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
|
PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of severe acute GVHD (aGVHD) till Day 100
Time Frame: 100 days after haploidentical hematopoietic cell transplantation
|
Participants will be evaluated for the occurrence of aGVHD, grades III-IV in the first 100 days after transplantation and the time to occurrence of aGVHD, grades III-IV will be recorded.
Severity of acute GVHD will be graded according to the CONSENSUS CRITERIA FOR GRADING OF ACUTE GVHD which has four Grades from Grade I to Grade IV.
The higher the Score, the Worse the outcome.
|
100 days after haploidentical hematopoietic cell transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Performance of the CliniMACS Prodigy® LP-TCRα/β-19-45RA(Trial Version)
Time Frame: Until Last Patient Last Visit(24 Months)
|
Performance of the CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version) will be assessed by calculating the log-depletion of TCRα/β+ and CD45RA+ cells
|
Until Last Patient Last Visit(24 Months)
|
Incidence of acute GVHD (aGVHD) till six months post-transplantation
Time Frame: 6 Months
|
Incidence of aGVHD, grade II-IV till six months post-transplantation will be evaluated.
The maximum grade and the time to occurrence of acute GVHD will be recorded.
Incidence and severity of acute GVHD will be graded according to the Consensus Criteria
|
6 Months
|
Neutrophil Engraftment
Time Frame: Day 7
|
Time to neutrophil engraftment will be defined as the first of three consecutive measurements of ANC ≥500/µL following conditioning regimen induced nadir, starting from the day of the first stem cell transplantation
|
Day 7
|
Platelet Engraftment
Time Frame: Day 0
|
Time to platelet engraftment will be defined as the first of three consecutive measurements of platelet count ≥20,000/µL without platelet transfusion support, starting from the day of the first stem cell transplantation.
|
Day 0
|
Chronic GVHD
Time Frame: 1 Year
|
Incidence and severity of chronic GVHD will be graded according to standard criteria for grading of chronic GVHD
|
1 Year
|
Non-relapse mortality (NRM)
Time Frame: Until Last patient last Visit(24 Months)
|
NRM is defined as death occurring in a patient between the first day of conditioning and day of last assessment (all visits throughout the study), not due to disease relapse/recurrence
|
Until Last patient last Visit(24 Months)
|
Infusion toxicity
Time Frame: 15 minutes, 30 minutes, 2 hours, and 4 hours post infusion
|
Maximum infusion toxicity on the days of transfusion will be evaluated by measuring the patient's blood pressure, heart rate, respiration rate and temperature one hour prior to the allograft infusion and then approximately 15 minutes, 30 minutes, 2 hours, and 4 hours post infusion
|
15 minutes, 30 minutes, 2 hours, and 4 hours post infusion
|
Graft failure
Time Frame: 30 Days
|
Primary graft failure is defined as the failure to achieve an ANC ≥500 cells/µL by Day +30 in the setting of donor chimerism < 5% using local methods
|
30 Days
|
Overall survival (OS)
Time Frame: Day 100 and through study completion, an average of 1 year post transplantation
|
OS defined as time from transplantation to death or last follow-up and will be assessed at Day 100 and after 1 year
|
Day 100 and through study completion, an average of 1 year post transplantation
|
Disease-free survival (DFS)
Time Frame: Day 100 and through study completion, an average of 1 year post transplantation
|
DFS is defined as the minimum time to relapse/recurrence, to death or to the last follow-up, from the time of transplantation and will be assessed at Day 100 and after 1 year
|
Day 100 and through study completion, an average of 1 year post transplantation
|
GVHD/relapse-free survival (GRFS)
Time Frame: GRFS will be assessed at Month 12 post transplantation
|
An event is defined as grade III-IV acute GVHD, moderate to severe chronic GVHD, disease relapse, or death by any cause.
GRFS will be assessed at 1 year.
|
GRFS will be assessed at Month 12 post transplantation
|
Immunosuppression-free survival (ISFS)
Time Frame: Assessed at 1 year with a starting point at Day 45 post-transplantation
|
Defined as being alive, relapse-free and off immunosuppressive therapy and will be assessed at 1 year with a starting point at Day 45 post-transplantation.
Immune suppression is defined as any systemic agents used to control or suppress GVHD.
|
Assessed at 1 year with a starting point at Day 45 post-transplantation
|
Relapse rate
Time Frame: 12 Months
|
Time to relapse will be calculated from the time of transplantation to evidence of relapse
|
12 Months
|
Hospitalization length/re-admission
Time Frame: Assessed at Day 30, Day 100 and at 12 Months post transplantation
|
Number of days that patients had to be hospitalized until discharge after transplantation, and after any subsequent occurrence of an event leading to re- hospitalization assessed
|
Assessed at Day 30, Day 100 and at 12 Months post transplantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 30, 2024
Primary Completion (Estimated)
April 30, 2027
Study Completion (Estimated)
April 30, 2027
Study Registration Dates
First Submitted
December 5, 2023
First Submitted That Met QC Criteria
January 15, 2024
First Posted (Actual)
January 25, 2024
Study Record Updates
Last Update Posted (Actual)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 29, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M-2018-334
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematological Malignancies
-
Tel-Aviv Sourasky Medical CenterMeir Medical Center; Max Planck Institute for Infection BiologyUnknownPediatric Solid Malignancies | Pediatric Hematological MalignanciesIsrael
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRelapsed/Refractory Hematological MalignanciesChina
-
AdaptimmuneRecruitingSolid and Hematological MalignanciesUnited States, Spain, Canada, United Kingdom
-
Kite, A Gilead CompanyEnrolling by invitationSolid and Hematological MalignanciesUnited States, Netherlands, Japan, Australia, France, Israel, Germany, Canada, United Kingdom
-
AstraZenecaParexelCompletedSolid and Hematological MalignanciesGermany
-
AdaptimmuneTerminatedSolid and Hematological MalignanciesUnited States, Canada
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineCompletedMyeloid Hematological MalignanciesUnited States
-
Centre Hospitalier Universitaire de BesanconTerminatedHematological Malignancies BFrance
-
Senti BiosciencesNot yet recruitingAML/MDS | CD33 Expressing Hematological Malignancies | FLT3 Expressing Hematological Malignancies
-
CASI Pharmaceuticals, Inc.CompletedRelapsed or Refractory Hematological MalignanciesCanada